Head rotation (HR) negatively affects balance and walking performance in people with multiple sclerosis (MS). Specifically, during walking, individuals with MS lose their walking rhythm for a few steps after HR, which represents a significant performance decline and may partly explain their increased risk of falling.
Nearly 25% of people with multiple sclerosis in our study reported wearing off prior to their next ocrelizumab infusion while on the standard 6-month dosing interval.